Generation Investment Management Adds $46M in STERIS plc ($STE)
The fund added over 219,000 shares, a 10.5% increase, in its latest SEC filing.
Key Points
- Generation Investment Management increased its stake in STERIS plc by 10.5%, adding 219,976 shares for a total of 2,308,459 shares valued at $479.1 million.
- STERIS plc, trading at $207.56, has a market cap of $20.2 billion and a P/E ratio of 26.17, with a 52-week range between $195.14 and $269.44.
- Analysts maintain a 'buy' consensus on STERIS with a mean target price of $256.86, while insiders, including the CEO, have been selling shares recently.
Generation Investment Management has increased its stake in STERIS plc (NYSE: STE) by 10.5%, according to its latest SEC filing. The fund added 219,976 shares, bringing its total holdings to 2,308,459 shares valued at approximately $479.1 million. This update reflects the fund's position as of the most recent reporting period.
What Changed in Generation Investment Management's STERIS Position
Generation Investment Management boosted its stake in STERIS plc by 10.5%, adding 219,976 shares to its portfolio. The fund now holds a total of 2,308,459 shares, up from 2,088,483 shares previously. This increase aligns with the company's reported value of $479.1 million.
Other Institutional Activity in STERIS
In recent institutional activity, BlackRock, Inc. reduced its holdings by 14,812 shares, ending with 9,026,621 shares valued at about $1.99 billion. Vanguard Capital Management LLC established a new position, holding 6,366,378 shares worth approximately $1.41 billion. State Street Corp grew its stake by 377,028 shares, reaching a total of 4,991,868 shares valued at $1.10 billion. Morgan Stanley increased its holdings by 554,445 shares, bringing its total to 4,394,263 shares worth around $971.7 million.
STERIS Stock Snapshot
Shares of STERIS plc (NYSE: STE) recently traded at $207.56. The company has a market capitalization of about $20.2 billion and a P/E ratio of 26.17. Its stock has experienced a 52-week low of $195.14 and a high of $269.44. The 50-day moving average is $215.95, while the 200-day moving average is $239.71. STERIS maintains a current ratio of 2.09 and a quick ratio of 1.34, with a debt-to-equity ratio of 29.00.
Recent Earnings
STERIS plc reported revenue of $5.94 billion, reflecting a growth rate of 7.3%. The company achieved a net margin of 13.18% and a return on equity of 11.37%. Earnings per share stood at $7.93. The next earnings report is scheduled for August 5, 2026.
Dividend
STERIS offers an annual dividend rate of $2.52, yielding 1.21% with a payout ratio of 31.02%. The ex-dividend date was not specified.
Insider Buying and Selling at STERIS plc
Recent insider transactions at STERIS plc show several executives selling shares. On June 5, 2026, President and CEO Daniel Carestio sold 1,374 shares at an average price of $212 under a planned sale. Other executives, including Sr. VP Julia Madsen and CFO Karen Burton, sold smaller amounts of shares on June 4, 2026, at prices around $212.24.
Analysts Set New Price Targets
On May 13, 2026, Keybanc maintained its 'buy' rating for STERIS with a price target of $269. The consensus among analysts is a 'buy' rating, with a mean target price of $256.86 based on seven analyst opinions.
About STERIS plc
STERIS plc is a healthcare company based in Mentor, Ohio, specializing in infection prevention products and services. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company provides a range of products and services including cleaning chemistries, sterility assurance products, and sterilization equipment. STERIS serves healthcare providers, medical device manufacturers, and pharmaceutical companies globally. Founded in 1985, the company employs around 17,937 people and is led by CEO Daniel A. Carestio.
Bottom Line
Generation Investment Management's increased stake in STERIS plc underscores its interest in the company's growth potential. Investors often track such filings to gauge institutional confidence, though it's important to remember that 13F filings are backward-looking and may not reflect current positions. With a strong market position and analyst support, STERIS remains a company to watch.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.